HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $49 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Cytokinetics (NASDAQ:CYTK) and maintains a $49 price target.
June 20, 2023 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Cytokinetics and maintains a $49 price target.
The reiteration of a Buy rating and maintenance of a $49 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for Cytokinetics' stock in the short term. This news is highly relevant and important for investors, as it suggests potential upside for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100